Clinical trials: Alzheimer Disease; Prodromal
Alzheimer Disease
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This is a Phase II, multicenter, open-label, single arm, PD study in participants with early (prodromal to mild) AD to evaluate the effect of a once weekly (Q1W) dosing regimen of gantenerumab on deposited amyloid as measured by…
- Trial name
- NCT04592341
- Testing
- Gantenerumab
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 192 people
- Sponsor
- Hoffmann-La Roche
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Prodromal Alzheimer's Disease
Exploring the Gut-Brain Axis in Ageing and Neurodegeneration
Neurodegenerative diseases are a major health concern due to their growing societal implications and economic costs. The identification of early markers of pathogenic mechanisms is one of the current main challenges.
- Conditions
- Healthy, Prodromal Alzheimer's Disease, Parkinson Disease, Multiple Sclerosis
- Trial name
- GutBrain (NCT05934188)
- Testing
- Magnetic Resonance Imaging, Neuropsychological protocol, Eating habits
- Where
- 3 sites in Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Camillo, Venezia, Italy
Down Syndrome, Alzheimer Disease
Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)
TriAL21 study is an interventional, open, one arm, prospective, national and single center study. A total of 200 patients with Down syndrome, aged 35 years and over, without diagnosis of Alzheimer's disease will be enrolled into…
- Trial name
- NCT03901261
- Testing
- Neuro-imaging, Lumbar puncture
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Jerome Lejeune
Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease
TMS for Cognitive Decline in Aging and Preclinical AD
In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical…
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Trial name
- NCT06956300
- Testing
- Active rTMS
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
TRC-PAD Program: In-Clinic Trial-Ready Cohort
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
- Trial name
- TRC-PAD (NCT04004767)
- Where
- 45 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI)…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- APECS (NCT01953601)
- Testing
- Verubecestat 12 mg (Parts 1 and 2), Verubecestat 40 mg (Parts 1 and 2)
- Volunteers
- 1,454 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Dementia
Financial Incentives and Recruitment to the APT Webstudy
This single-blind, three-arm, randomized, controlled trial will assess the impact of messages and financial incentives on the enrollment of demographically diverse individuals to the Alzheimer Prevention Trials (APT) Webstudy.
- Conditions
- Alzheimer Disease, Dementia, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- FIND-AD (NCT06033066)
- Testing
- Financial Incentives, Message
- Where
- United States
- Volunteers
- 44,844 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech, can predict change in Preclinical Alzheimer's Clinical Composite with semantic processing (PACC5)…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- FUTURE-US (NCT04951284)
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Neurodegenerative Diseases, Parkinson Disease
Saliva and Extracellular Vesicles for Neurodegenerative Diseases
Early diagnosis of Neurodegenerative diseases (NDDs) and accurate patient profiling are key goals needed to tailor prompt personalized therapeutic strategies that can significantly impact disease progression and patients' quality…
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Alzheimer Disease, Parkinsonism
- Trial name
- MINERVA (NCT06869135)
- Testing
- Saliva collection, longitudinal
- Where
- 5 sites in Italy
- Volunteers
- 242 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Alzheimer Disease
Neuroelectrical Biomarkers for Alzheimer's Disease Stages
Recent diagnostic criteria for Alzheimer's disease (AD) recognize an extended spectrum of AD stages as part of the disease, including a preclinical stage.
- Trial name
- ESTIMATE (NCT01880151)
- Testing
- EEG
- Where
- France
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer's Disease - MCI
Noninvasive Brain Stimulation for pAD
Episodic memory refers to the conscious recalling of a personal experience and includes information of an event and the context in which the event took place.
- Trial name
- pADmemory (NCT05468268)
- Testing
- 20 Hz rTMS
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Università degli Studi di Trento
Subjective Cognitive Decline, Mild Cognitive Impairment
Cognitive Training and Brain Stimulation in Prodromal Alzheimer's Disease
The aim of this study is to investigate whether a tDCS-accompanied intensive cognitive training of working memory leads to performance improvement in individuals with prodromal Alzheimer's disease.
- Trial name
- AD-Stim (NCT04265378)
- Testing
- anodal tDCS, Intensive cognitive training
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- University Medicine Greifswald
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Deferiprone to Delay Dementia (The 3D Study)
This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the safety and efficacy of Deferiprone in participants with Prodromal Alzheimer's Disease (pAD) and Mild Alzheimer's Disease (mAD).
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease, Mild Alzheimer's Disease
- Trial name
- NCT03234686
- Testing
- Deferiprone 600mg delayed release tablets
- Where
- 8 sites in Australia
- Volunteers
- 81 people
- Sponsor
- Neuroscience Trials Australia
Mild Cognitive Impairment, Alzheimer Disease
Senicapoc in Alzheimer's Disease
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD.
- Trial name
- Senicapoc (NCT04804241)
- Testing
- Senicapoc
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED (NCT04828122)
- Where
- 4 sites in United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer's Disease
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks.
- Trial name
- NCT00890890
- Testing
- Avagacestat
- Where
- 64 sites in United States, Canada and 4 more
- Volunteers
- 263 people
- Sponsor
- Bristol-Myers Squibb
Neuropathology
Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?
Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain.
- Trial name
- ALZ-OREX (NCT05629871)
- Testing
- Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems
- Where
- 3 sites in France
- Volunteers
- 132 people
- Sponsor
- University Hospital, Montpellier
Alzheimer's Disease
" The Eyes Have it " : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease
Alzheimer's disease (AD) has a prolonged prodromal phase before the stage of dementia. Subtle executive cognitive function deficits can be detected at this early pre-dementia phase, more than 10 years before dementia.
- Trial name
- LYLO (NCT01630525)
- Testing
- Neuropsychological assessment, ophthalmologic checkup, Automated non-invasive oculometry
- Where
- 3 sites in France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Alzheimer's Disease
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will…
- Trial name
- COGNITE (NCT02547818)
- Testing
- ALZT-OP1a, ALZT-OP1b
- Where
- 121 sites in United States, Australia and 5 more
- Volunteers
- 620 people
- Sponsor
- AZTherapies, Inc.